ABT — Abbott Laboratories Balance Sheet
0.000.00%
Last trade - 00:00
- $186.15bn
- $193.77bn
- $40.11bn
- 85
- 26
- 75
- 66
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 4,140 | 7,148 | 10,249 | 10,170 | 7,279 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,425 | 6,414 | 6,487 | 6,218 | 6,565 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 15,667 | 20,441 | 24,239 | 25,224 | 22,670 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 8,972 | 10,130 | 10,112 | 10,278 | 11,276 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 67,887 | 72,548 | 75,196 | 74,438 | 73,214 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 10,863 | 11,907 | 13,105 | 15,489 | 13,841 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 36,799 | 39,764 | 39,394 | 37,752 | 34,611 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 31,088 | 32,784 | 35,802 | 36,686 | 38,603 |
Total Liabilities & Shareholders' Equity | 67,887 | 72,548 | 75,196 | 74,438 | 73,214 |
Total Common Shares Outstanding |